Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia | MicrobiomeTrials← Back to trialsNCT04959201
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-11-30Est. Completion: 2026-12
Enrollment target: 90 participants Locations- Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan
Other microbiome trials you might be interested in
fMRI
Despite the clear importance of adolescence in the emergence of a number of disease states and processes, there is surpr…
Bethesda, United States
SchizophreniaParkinson's Disease
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volun…
Bethesda, United States
Psychotic DisordersFamily Members
Anosognosia
Paranoia
Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leave…
Edmonton, CanadaEst. completion Dec 1, 2028